Affiliation
Ministry of Health, Colombo 01000, Sri Lanka.Issue Date
2019
Metadata
Show full item recordCitation
Joseph N, Choudhury A. SABR versus conventional fractionation regimens in NSCLC. Lancet Oncol. 2019 May;20(5):e231.Journal
The Lancet OncologyDOI
10.1016/S1470-2045(19)30180-9PubMed ID
31044708Additional Links
https://dx.doi.org/10.1016/S1470-2045(19)30180-9Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(19)30180-9
Scopus Count
Collections
Related articles
- SABR versus conventional fractionation regimens in NSCLC.
- Authors: Addeo A, Buffoni L
- Issue date: 2019 May
- SABR versus conventional fractionation regimens in NSCLC - Authors' reply.
- Authors: Ball D, Herschtal A
- Issue date: 2019 May
- Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
- Authors: Phillips I, Sandhu S, Lüchtenborg M, Harden S
- Issue date: 2019 Oct
- Do SABR-related toxicities for lung cancer depend on treatment delivery?
- Authors: Morias S, Marcu LG, Short M, Giles E, Bezak E
- Issue date: 2018 Sep
- SABR in NSCLC--the beginning of the end or the end of the beginning?
- Authors: Brada M, Pope A, Baumann M
- Issue date: 2015 Feb